ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) has received a second near-term payment of $5 million from Axion Bio, previously known as SynBioTx, a Wednesday Hong Kong bourse filing said.
The company had, in August 2024, granted Axion Bio an exclusive license for the research, development, and commercialization of the anti-tumor drugs outside of Mainland China, Hong Kong, Macau, and Taiwan.
As of Wednesday, the pharmaceutical firm has received a total of $20 million in upfront and near-term payments under the license contract.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.